All articles tagged with #enhertu
The FDA has approved AstraZeneca and Daiichi Sankyo's drug Enhertu, in combination with Roche's Perjeta, as a first-line treatment for advanced HER2-positive breast cancer, based on a study showing improved progression-free survival and tumor response.
Enhertu, a cancer drug developed by Daiichi Sankyo and AstraZeneca, has shown in clinical trials to stall tumor growth in metastatic breast cancer for over a year, significantly longer than standard chemotherapy. This breakthrough could change the standard of care for hormone receptor-positive, metastatic breast cancer, benefiting patients with even minimal HER2 protein expression.